Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/132275
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Traditional Chinese medicine for acute myocardial infarction in Western medicine hospitals in China
Author: Spatz, E.S.
Wang, Y.
Beckman, A.L.
Wu, X.
Lu, Y.
Du, X.
Li, J.
Xu, X.
Davidson, P.M.
Masoudi, F.A.
Spertus, J.A.
Krumholz, H.M.
Jiang, L.
Citation: Circulation: Cardiovascular Quality and Outcomes, 2018; 11(3):e004190-1-e004190-11
Publisher: American Heart Association; Wolters Kluwer
Issue Date: 2018
ISSN: 1941-7713
1941-7705
Statement of
Responsibility: 
Erica S. Spatz, Yongfei Wang, Adam L. Beckman, Xuekun Wu, Yuan Lu, Xue Du, Jing Li, Xiao Xu, Patricia M. Davidson, Frederick A. Masoudi, John A. Spertus, Harlan M. Krumholz, Lixin Jiang
Abstract: Background: Amid national efforts to improve the quality of care for people with cardiovascular disease in China, the use of traditional Chinese medicine (TCM) is increasing, yet little is known about its use in the early management of acute myocardial infarction (AMI). Methods and Results: We aimed to examine intravenous use of TCM within the first 24 hours of hospitalization (early IV TCM) for AMI. Data come from the China Patient-centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction, restricted to a large, representative sample of Western medicine hospitals throughout China (n=162). We conducted a chart review of randomly sampled patients with AMI in 2001, 2006, and 2011, comparing early intravenous TCM use across years, predictors of any early intravenous TCM use, and association with in-hospital bleeding and mortality. From 2001 to 2011, early intravenous TCM use increased (2001: 38.2% versus 2006: 49.1% versus 2011: 56.1%; P<0.01). Nearly all (99%) hospitals used early intravenous TCM. Salvia miltiorrhiza was most commonly prescribed, used in one third (35.5%) of all patients admitted with AMI. Patients receiving any early intravenous TCM, compared with those who did not, were similar in age and sex and had fewer cardiovascular risk factors. In multivariable hierarchical models, admission to a secondary (versus tertiary) hospital was most strongly associated with early intravenous TCM use (odds ratio: 2.85; 95% confidence interval: 1.98–4.11). Hospital-level factors accounted for 55% of the variance (adjusted median odds ratio: 2.84). In exploratory analyses, there were no significant associations between early intravenous TCM and in-hospital bleeding or mortality. Conclusions: Early intravenous TCM use for AMI in China is increasing despite the lack of evidence of their benefit or harm. There is an urgent need to define the effects of these medications because they have become a staple of treatment in the world’s most populous country.
Keywords: Cardiovascular diseases; complementary therapies; medicine, Chinese traditional; quality of health care; Salvia miltiorrhiza
Rights: © 2018 The Authors. Circulation: Cardiovascular Quality and Outcomes is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.
DOI: 10.1161/CIRCOUTCOMES.117.004190
Published version: http://dx.doi.org/10.1161/circoutcomes.117.004190
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_132275.pdfPublished version429.98 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.